Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
22 août 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has...
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
28 juin 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...
Neuronascent Announces the Expansion of its Board of Directors
12 avr. 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer...
Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease
08 nov. 2022 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract entitled “Reduction of plasma p-Tau181 from a Phase 1a Randomized Trial of NNI-362 in a healthy aged...
Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome
01 juin 2022 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., June 01, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc, today announced that the U.S. Food and Drug Administration (FDA) granted “Orphan Drug Designation” for the company’s NNI-351...
Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome
24 mai 2022 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage biopharmaceutical company discovering and developing neuron-generating therapies for rare developmental...
Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease
30 mars 2022 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative therapies for age-related brain...
Neuronascent Announces Publication of Pre-clinical Results of Alzheimer’s Disease Clinical Candidate, NNI-362 in SCR&T Journal
20 janv. 2021 06h00 HE
|
Neuronascent, Inc.
CLARKSVILLE, Md., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced the publication of results of their novel...
Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer's Disease
07 mai 2019 05h00 HE
|
Neuronascent, Inc.
CLARKSVILLE, Md., May 07, 2019 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has...
Neuronascent Awarded $2.25 Million NIH Grant to Develop a Regenerative Therapeutic for Alzheimer’s Disease
19 sept. 2018 06h00 HE
|
Neuronascent, Inc.
CLARKSVILLE, Md., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute on Aging (NIA), part of...